Combined dry extract BNO 1016 is a herbal drug commonly used for rhinosinusitis therapy. It is known that a significant role in rhinosinusitis pathogenesis is played by an inflammatory reaction in maxillary sinuses of the nasal cavity. At the initial stage of any inflammation the largest impact is caused by leukotrienes. Major chronic rhinosinusitis (CRS) according to the guideline EPOS-2020 include facial pain as clinical diagnostic criteria for rhinosinusitis. Therefore, it is reasonable to study the analgesic effects of the combined dry extract BNO 1016 on the model of zymozan- induced hyperalgesia. The tested drug is the combined dry extract BNO 1016 ("Bionorica SE", Germany) at different dose levels. The reference drug is ibuprofen. Leukotriene hyperalgesia was induced by subplantar injection of zymozan into the paw of Wistar rats. Pain threshold was evaluated with Ugo-Basil analgesimeter and analgesic activity was calculated together with mean effective dose (ED50) with help of the Probit Analysis. The highest analgesic activity was observed at a dose level of 500 mg/kg of BNO 1016 during all time-points of the experiment and reached 169.5% 3h after hyperalgesia onset. The analgesic activity of BNO 1016 at doses of 50 mg/kg in 1h, 2h, 3h after induction hyperalgesia, 150 mg/kg and 500 mg/ kg was credibly higher than that of Ibuprofen at all time-points of the experiment. Based on the experimental data, the index of ED50 for analgesic activity of BNO 1016 was calculated with Probit Analysis. The combined dry extract BNO 1016 shows a high level of analgesic activity in the leukotriene-depended hyperalgesia model, which is very promising for the improvement of treatment of patients with CRS, but additional preclinical and clinical researches are reasonable.